QUOTE AND NEWS
DailyFinance  Apr 14  Comment 
HOUSTON, TX -- (Marketwired) -- 04/14/14 -- One World Holdings, Inc. (OTCQB: OWOO) ("One World") announced today that its subsidiary, The One World Doll Project, has become an approved vendor to major regional hypermarket store chain, HEB...
Benzinga  Apr 8  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and Toxicological Species Responses to TLR-3 Activation" in the current issue of the American...
StreetInsider.com  Mar 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Plans+App+Submissions+in+LatAm+for+Ampligen/9264034.html for the full story.
Benzinga  Feb 4  Comment 
Hemispherx Biopharma, Inc. (NYSE: HEB) (the "Company" or "Hemispherx"), presented a summary of the results of its Phase I/II study from the poster presentation entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod...
StreetInsider.com  Jan 21  Comment 
Amarin Corporation plc (Nasdaq: AMRN) 23.8% LOWER; announced today that the Division of Metabolism and Endocrinology Products (DMEP) within the U.S. Food and Drug Administration (FDA) has notified Amarin in connection with Amarin's request for...
StreetInsider.com  Jan 14  Comment 
52-Week High: Hemispherx Biopharma (AMEX: HEB) $0.44. Hemispherx Biopharma seeing upside above the $0.40 mark as the company heads into its presentation at the Biotech Showcase held in conjunction with the 32nd JP Morgan Healthcare Conference in...
Benzinga  Jan 7  Comment 
Hemispherx Biopharma (NYSE MKT: HEB) today announced publication of an article entitled "Emergence of a novel drug resistant H7N9 influenza virus: Evidence based clinical potential of a natural IFN-alpha for infection control and treatment" in...
StreetInsider.com  Dec 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Bio+%28HEB%29+Gets+FDA+Authorization+for+Expansion+AmpligenFluMist+Intranasal+Trial/8958412.html for the full story.
StreetInsider.com  Nov 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+CFO+Resigns/8899910.html for the full story.
StreetInsider.com  Nov 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Hemispherx+Biopharma+%28HEB%29+Posts+Q3+Loss+of+3cShare/8868417.html for the full story.





You may also be interested in articles related to Hemispherx BioPharma (HEB):

 
TOP CONTRIBUTORS
Hemispherx Biopharma, Inc (HEB) is a medical research company focusing on a new group of medicinal products knows as nucleic acid compounds.

HEB’s main focus is the treatment of Influenza and various Flu Strains through Ampligen®. However, Ampligen® may also serve as a treatment for Chronic Fatigue Syndrome (CFS). Ampligen®, the company’s main candidate is expected to receive FDA approval in the coming weeks. Other projects include Alferon N® which works as an indicator for recurring herpes.

Lack of diversified products, alternative remedies, failure to be approved by the FDA, and possible lawsuits from patients after approval, make this a very high risk company. But if approval by the FDA and wide acceptance of doctors world wide is accomplished many investors expect the stock value to rise too significantly too pass this investment by.

It is a New York City based corporation trading on AMEX.



References

http://www.google.com/finance?q=heb , http://www.hemispherx.net , http://www.pr-inside.com/post-approval-hemispherx-ampligen-pps-r1293461.htm ,

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki